Goldman Sachs Puts Bullish Spin on Struggling Biotech Contineum Therapeutics

Goldman Sachs has initiated coverage on Contineum Therapeutics Inc. (CTNM), assigning an Early-Stage Biotech rating to the stock. The company's market capitalization stands at $471 million, with a current price of $12.51 per share. This represents a decline of 5.3% over the past week.

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for inflammatory and fibrotic indications. The company's lead candidate, PIPE-791, is a brain-penetrant lysophosphatidic acid 1 receptor antagonist currently being evaluated in the Phase 2 PROPEL-IPF trial for the treatment of idiopathic pulmonary fibrosis.

Following positive exploratory Phase 1b results, Contineum Therapeutics may explore PIPE-791 as a potential treatment for chronic pain. According to InvestingPro data, the company holds more cash than debt on its balance sheet with a current ratio of 37.17, providing substantial financial flexibility for its clinical programs.

Goldman Sachs analyst Andrea Newkirk assumed coverage on the company, maintaining confidence in Contineum Therapeutics' prospects despite recent setbacks. The company's phase 2 trial for the selective M1R antagonist PIPE-307/JNJ-5120 did not meet its primary endpoint for treating major depressive disorder.